Page 26 - Article

Which roles do IDO and TDO play in Immunotherapy? Immune evasion is one of the identifying hallmarks of cancer and researchers are investigating the complex mechanisms that enable cancer

A recent publication by Torres et al. has found that B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-beta1/HR

Statins are HMG-CoA reductase inhibitors, well-known  medications for treating Hypercholesterolemia. Simvastatin is a member of this "Statin family" and controls

PGE₂

A crosstalk between cancer and immune cells is established during cancers. The immune system is able to fight against tumour cells (see my previous post "Immunosurveillance: Crosstalk between cancer and

Matrix components are key R&D elements in pharmaceutical and cosmetology with tremendous impacts on tissue regeneration, skin repair,

Thousands of researchers spend time pampering their primary cells and cell lines every day, with the aim of defining their optimal cell culture conditions. Researchers are in effect trying to control numerous

Classically, it was known that CD4⁺ T cells, upon activation and expansion, develop into different T helper cell subsets with different cytokine profiles and distinct effector functions to effect

Immunoediting of cytokine signals provides another area of pathways which tumours utilise to evade and potentially escape from immunological targeting. This post aims at shedding some light into the Tumour

Rat liver tritosomes are hepatic lysosomes that have been loaded with Tyloxapol (Triton WR 1339), a non-ionic surfactant. Tyloxapol is taken up by hepatocytes through endocytosis and is trafficked to lysosomal

Histone Methyltransferases (ex. EZH1 and EZH2, and G9a) and their counter-parts (Histone demethylases like JARID1, the KDM4, and the JMJD family) have become promising targets for inhibitor screenings,